Ipilimumab — Drug Intelligence | 88 EU Trials

Filter these 88 trials by condition, phase, country and more.

Open in Search →

88 Registered trials

30 Recruiting

46 Completed trials

50 Sponsors

18 Countries

Phase III

Phase II

Phase I/II

Phase III: 23 Phase II/III: 6 Phase II: 36 Phase I/II: 13 Phase IV: 3 Phase I (Other): 4 Phase I (FiH): 3

Oversight events:

3 serious breaches 8 temporary halts 1 urgent safety measure 1 unexpected event across 6 trials

View oversight register →

Indications tested

Non-small cell lung cancer 5 Uveal melanoma 4 Malignant melanoma 3 Malignant melanoma stage IV 2 Malignant melanoma stage III 2 Metastatic renal cell carcinoma 2 Pleural mesothelioma malignant 2 Colorectal cancer 2 Metastatic malignant melanoma 2 Hepatocellular carcinoma 2 Colon cancer stage IV 1 Colorectal cancer stage III 1

Sponsors using this IMP

Bristol Myers Squibb International Corporation 10 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting 10 Bristol-Myers Squibb Services Unlimited Company 8 Amsterdam UMC Stichting 3 Institut Gustave Roussy 3 Pfizer Inc. 3 Region Hovedstaden 3 European Organisation For Research And Treatment Of Cancer 2 Exelixis Inc. 2 Ideaya Biosciences Inc. 2 Odense University Hospital 2 UZ Brussel 2

All trials — page 2

88 total

A phase IB clinical trial on neoadjuvant and intraoperative intracranial administration of triple immune checkpoint blockade plus myeloid d… Recruiting

2024-517842-33-01 Phase I (Other) 1 country UZ Brussel
A randomized, run-in, phase II study of nivolumab combined with ipilimumab and oral decitabine/cedazuridine (ASTX727) or nivolumab combined … Recruiting

2024-518891-29-00 Phase II 1 country Fondazione NIBIT Onlus
A personalised approach based on blood and tumor characteristics to guide the post-surgical clinical path of patients with operable locoregi… Recruiting

2023-509851-15-00 Phase III 3 countries Ifom Istituto Fondazione Di Oncologia Molecolare Ets In Breve Ifom Ets
IDE196 (Darovasertib) in Combination with Crizotinib as First-line Therapy in Metastatic Uveal Melanoma Recruiting

2023-506686-66-01 Phase II/III 7 countries Ideaya Biosciences Inc.
Uptake and biodistribution of 89Zirconium-labeled ipilimumab in ipilimumab treated patients with metastatic melanoma Recruiting

2024-516547-11-00 Phase II 1 country Stichting Amsterdam UMC
NOvel Immunotherapy strategies for advanced Triple negative breast Cancer (TNBC) patients: TONIC-3 trial Recruiting

2023-507875-23-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
A Phase III Randomized Controlled Multicentre Trial of Percutaneous Hepatic Perfusion in Combination with Ipilimumab and Nivolumab Compared … Recruiting

2023-508156-20-00 Phase III 2 countries Vaestra Goetalandsregionen
CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA Recruiting

2023-503317-29-00 Phase III 10 countries Institut Gustave Roussy
Immune-Related Rheumatological and neurological Adverse Events study. Recruiting

2024-516631-27-00 Phase II 1 country Stichting Amsterdam UMC
Immunotherapy in patients with early dMMR rectal cancer. A Danish DCCG phase II trial Recruiting

2022-500646-14-00 Phase II 1 country Odense University Hospital
Immunological variables associated to ICI toxicity in cancer patients Recruiting

2023-505360-11-00 Phase II 1 country Institut Jules Bordet
Pan tumor Roll Over Study Recruiting

2023-506914-32-00 Phase II 10 countries Bristol-Myers Squibb Services Unlimited Company
Pre-operative phase II trial for breast cancer with nivolumab in combination with novel IO (BELLINI trial) Recruiting

2024-515080-54-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Efficacy of immunotherapy in melanoma patients with brain metastases treated with steroids. The MEMBRAINS trial Recruiting

2024-516585-11-00 Phase II 1 country Region Hovedstaden
Adjuvant immunotherapy after salvage surgery in head and neck squamous cell carcinoma: phase 2 trial evaluating the efficacy and the toxicit… Recruiting

2024-516810-39-00 Phase II 1 country Institut Gustave Roussy
A randomized phase II clinical trial on intratumoral AS01B/ipilimumab plus intravenous nivolumab with or without autologous CD1c(BDCA-1)+ / … Recruiting

2024-517094-24-00 Phase I/II 1 country UZ Brussel
Neoadjuvant immune checkpoint inhibition and novel IO combinations in early-stage colon cancer - the NICHE trial Recruiting

2024-513314-35-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
DRUP trial Recruiting

2023-509152-33-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
A Study of Subcutaneous Nivolumab plus Intravenous Ipilimumab and Chemotherapy in Participants with Previously Untreated Metastatic or Recur… Ended

2024-520108-25-00 Phase II 5 countries Bristol-Myers Squibb Services Unlimited Company
A phase 1b-2 study of mitomycin-C / capecitabine chemoradiotherapy combined with ipilumimab and nivolumab or nivolumab monotherapy as bladde… Ended

2023-509460-19-00 Phase I/II 1 country Amsterdam UMC
Safe Stop ipi-nivo Ended

2024-516938-34-00 Phase III 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Phase III Trial of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed vs. Investigator’s Choice of the Standard of Care … Ended

2023-503231-17-00 Phase III 9 countries AstraZeneca AB
A window-of-opportunity trial with high-dose vitamin C to enhance neoadjuvant immune checkpoint therapy in mismatch repair proficient colore… Ended

2022-502524-41-00 Phase II 1 country ASST Grande Ospedale Metropolitano Niguarda
PRODIGE 81-FFCD 2101-TRIPLET: Study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patien… Ended

2022-501217-31-00 Phase II/III 1 country Fondation Franc.Cancerologie Digestive

Showing 25–48 of 88 trials

← All drugs A–Z